AHA Scientific Sessions 2019

By Dave Muoio 04:18 pm November 22, 2019
There are few clinical areas more in need of innovation than heart disease. It’s the leading killer among men and women in the US, accounting for one in every four deaths by the CDC’s numbers, and yet it’s also a body of health conditions that could be substantially mitigated through a number of lifestyle and behavior changes. So of course it’s little surprise that cardiovascular health and care...
By Dave Muoio 04:07 pm November 19, 2019
Device regulation is a hurdle for any medical tech company, but doubly so for startups hoping to strike it big with their very first digital health product. With limited resources and experience, pushing a device through the FDA’s door and onto the market is a multi-year gauntlet of validation, documentation and, unfortunately, frustration. To help young companies take a bit of the guesswork out...

Photo courtesy of Janssen Pharmaceutical Companies. From left to right: panel moderator Patrick Wayte, Dr. C. Michael Gibson and Dr. Paul Stoffels.

By Dave Muoio 01:23 pm November 18, 2019
Due to the promises of lower costs, simple scaling and greater patient engagement, digital technologies are all but an inevitability for the drug trials of tomorrow, according to experts from pharma and the clinical research community speaking this weekend at the American Heart Association Scientific Sessions in Philadelphia. These comments were accompanied by the official kickoff of CHIEF-HF,...
By Dave Muoio 03:25 pm November 17, 2019
A half dozen digital health startups went head to head this weekend in a pitch contest hosted by the American Heart Association. The competition’s cohort ranged from well-known heavy hitters like Welldoc to Korean hospital spinout Vuno, but in the end it was Pittsburgh-based Forest Devices that claimed top honors from both the contest’s eight judges and its audience. “Our solution is AlphaSTROKE...
By Dave Muoio 12:06 pm November 15, 2019
Livongo is touting new data regarding the efficacy of its device-and-coaching disease management platform, this time among those using its Livongo for Hypertension and Livongo for Diabetes products together. The results, which are set to be formally presented this weekend at the American Heart Association Scientific Sessions 2019, identified significant decreases in hypertensive blood pressure as...